Prateek Sharma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Prateek Sharma has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Rajani Mathur
Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research, Delhi Pharmaceutical Sciences and Research University, New Delhi, India
3 shared publications Jayachandran Nair
DIPSAR
2 shared publicationsThirumurthy Velpandian
All India Institute of Medical Sciences
2 shared publications- Ajay Kumar Pal
Department of Pharmacology Delhi Pharmaceutical Sciences and Research University (DPSRU) New Delhi India
1 shared publication - Alishan Zia
Department of Pharmacology, Delhi Pharmaceutical Sciences and Research University, New Delhi 110017, India
1 shared publication Anurag Sinh
DIPSAR
1 shared publication
Latest Publications
- Open Access
- 27 May 2022
- Published by MDPI AG in Pathophysiology
- Vol. 29 (2) , 200-222
Metabolomics and EMT Markers of Breast Cancer: A Crosstalk and Future Perspective
Cancer cells undergo transient EMT and MET phenomena or vice versa, along with the parallel interplay of various markers, often correlated as the determining factor in decoding metabolic profiling of breast cancers. Moreover, various cancer signaling pathways and metabolic changes occurring in breast cancer cells modulate the expression of such markers to varying extents. The existing research completed so far considers the expression of such markers as determinants regulating the invasiveness and survival of breast cancer cells. Therefore, this manuscript is crosstalk among the expression levels of such markers and their correlation in regulating the aggressiveness and invasiveness of breast cancer. We also attempted to cover the possible EMT-based metabolic targets to retard migration and invasion of breast cancer.
- 27 May 2022
- Published by MDPI AG in Pathophysiology
- Vol. 29 (2) , 200-222
Open AccessMetabolomics and EMT Markers of Breast Cancer: A Crosstalk and Future Perspective
Cancer cells undergo transient EMT and MET phenomena or vice versa, along with the parallel interplay of various markers, often correlated as the determining factor in decoding metabolic profiling of breast cancers. Moreover, various cancer signaling pathways and metabolic changes occurring in breast cancer cells modulate the expression of such markers to varying extents. The existing research completed so far considers the expression of such markers as determinants regulating the invasiveness and survival of breast cancer cells. Therefore, this manuscript is crosstalk among the expression levels of such markers and their correlation in regulating the aggressiveness and invasiveness of breast cancer. We also attempted to cover the possible EMT-based metabolic targets to retard migration and invasion of breast cancer.
- Open Access
- 25 April 2022
- Published by Wiley
Translation of hydroethanolic extract of leaves of Psidium guajava Linn for pediatric non-alcoholic fatty liver disease
To develop hydroethanolic extract of leaves of Psidium guajava L. (Myrtaceae), identify novel target and lead compound for pediatric non alcoholic fatty liver disease (ped-NAFLD). Hydroethanolic extract (PG-HM) and sequential fractions of locally collected leaves of P.guajava were prepared and standardized for quercetin content using LC-MS/MS. The effect of PG-HM on markers of ped-NAFLD in weaned rats with unrestricted access to liquid fructose (15%) till puberty and early adulthood, was evaluated. The PG-HM was investigated using 1) HepG2 cells grown in fructose containing medium for intercellular signalling, 2) isolated murine hepatocytes for mitochondrial effects, 3) jejunum isolated from fructose drinking rats for effect on ex vivo fructose transport, 4) molecular dynamics for in silico binding of quercetin with GLUT5, 5) normal rats for oral pharmacokinetics. The quercetin content in PG-HM was 3630.66 ± 17.61 ng ml-1 and the Cmax and Tmax were 140.527 ± 5.718 ng ml-1 and 0.75 ± 0.079 h, respectively. The PG-HM mitigated ped-NAFLD through hepatic signalling pathways of 1) leptin-insulin (Akt/FOX-O1/SREBP-1c), 2) hypoxia-inflammation (HIF-1ɑ/VEGF, TNF-ɑ), 3) mitochondrial function (complexes I-V), 4) oxidative stress (MDA, GSH, SOD) and 5) glycolysis/gluconeogenesis/de novo lipogenesis (hexokinase, phosphofructokinase, ketohexokinase, aldehyde dehydrogenase). For the first time, the PG-HM is reported to reduce and delay the fructose transport across jejunum that may be implicated to the binding of quercetin with GLUT5. For prevention and treatment of ped-NAFLD, the PG-HM, GLUT5 and quercetin are evidenced as dietary supplement, drug target and lead compound, respectively.
- 25 April 2022
- Published by Wiley
Open AccessTranslation of hydroethanolic extract of leaves of Psidium guajava Linn for pediatric non-alcoholic fatty liver disease
To develop hydroethanolic extract of leaves of Psidium guajava L. (Myrtaceae), identify novel target and lead compound for pediatric non alcoholic fatty liver disease (ped-NAFLD). Hydroethanolic extract (PG-HM) and sequential fractions of locally collected leaves of P.guajava were prepared and standardized for quercetin content using LC-MS/MS. The effect of PG-HM on markers of ped-NAFLD in weaned rats with unrestricted access to liquid fructose (15%) till puberty and early adulthood, was evaluated. The PG-HM was investigated using 1) HepG2 cells grown in fructose containing medium for intercellular signalling, 2) isolated murine hepatocytes for mitochondrial effects, 3) jejunum isolated from fructose drinking rats for effect on ex vivo fructose transport, 4) molecular dynamics for in silico binding of quercetin with GLUT5, 5) normal rats for oral pharmacokinetics. The quercetin content in PG-HM was 3630.66 ± 17.61 ng ml-1 and the Cmax and Tmax were 140.527 ± 5.718 ng ml-1 and 0.75 ± 0.079 h, respectively. The PG-HM mitigated ped-NAFLD through hepatic signalling pathways of 1) leptin-insulin (Akt/FOX-O1/SREBP-1c), 2) hypoxia-inflammation (HIF-1ɑ/VEGF, TNF-ɑ), 3) mitochondrial function (complexes I-V), 4) oxidative stress (MDA, GSH, SOD) and 5) glycolysis/gluconeogenesis/de novo lipogenesis (hexokinase, phosphofructokinase, ketohexokinase, aldehyde dehydrogenase). For the first time, the PG-HM is reported to reduce and delay the fructose transport across jejunum that may be implicated to the binding of quercetin with GLUT5. For prevention and treatment of ped-NAFLD, the PG-HM, GLUT5 and quercetin are evidenced as dietary supplement, drug target and lead compound, respectively.
- Open Access
- 29 October 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 15950
Molecular and Metabolic Markers of Fructose Induced Hepatic Insulin Resistance in Developing and Adult Rats are Distinct and Aegle marmelos is an Effective Modulator
The time course of pathogenesis of fructose mediated hepatic insulin resistance (HepIR) is not well-delineated and we chronicle it here from post-weaning to adulthood stages. Weaned rats were provided for either 4 or 8 weeks, i.e., upto adolescence or adulthood, chow + drinking water, chow + fructose, 15% or chow + fructose, 15% + hydroalcoholic extract of leaves of Aegle marmelos (AM-HM, 500 mg/kg/d, po) and assessed for feed intake, fructose intake, body weight, fasting blood sugar, oral glucose tolerance test, HOMA-IR, insulin tolerance test and lipid profile. Activities of enzymes (glucose-6-phosphatase, hexokinase, phosphofructokinase, aldehyde dehydrogenase), hormones (leptin, ghrelin, insulin), insulin signaling molecules (Akt-PI3k, AMPK, JNK) hallmarks of inflammation (TNF-α), angiogenesis (VEGF), hypoxia (HIF-1), lipogenesis (mTOR) and regulatory nuclear transcription factors of de novo lipogenesis and hepatic insulin resistance gene (SREBP-1, FoxO1) that together govern the hepatic fructose metabolism, were also studied. The effect of fructose-rich environment on metabolic milieu of hepatocytes was confirmed using (human hepatocellular carcinoma) HepG2 cells. Using in vitro model, fructose uptake and glucose output from isolated murine hepatocytes were measured to establish the HepIR under fructose environment and delineate the effect of AM-HM. The leaves from the plant Aegle marmelos (L) Correa were extracted, fractionated and validated for rutin content using LC-MS/MS. The rutin content of extract was quantified and correlated with oral pharmacokinetic parameters in rat. The outcomes of the study suggest that the molecular and metabolic markers of fructose induced HepIR in developing and adult rats are distinct. Further, AM-HM exerts a multi-pronged attack by raising insulin secretion, augmenting insulin action, improving downstream signaling of insulin, reducing overall requirement of insulin and modulating hepatic expression of glucose transporter (Glut2). The butanol fraction of AM-HM holds promise for future development.
- 29 October 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 15950
Open AccessMolecular and Metabolic Markers of Fructose Induced Hepatic Insulin Resistance in Developing and Adult Rats are Distinct and Aegle marmelos is an Effective Modulator
The time course of pathogenesis of fructose mediated hepatic insulin resistance (HepIR) is not well-delineated and we chronicle it here from post-weaning to adulthood stages. Weaned rats were provided for either 4 or 8 weeks, i.e., upto adolescence or adulthood, chow + drinking water, chow + fructose, 15% or chow + fructose, 15% + hydroalcoholic extract of leaves of Aegle marmelos (AM-HM, 500 mg/kg/d, po) and assessed for feed intake, fructose intake, body weight, fasting blood sugar, oral glucose tolerance test, HOMA-IR, insulin tolerance test and lipid profile. Activities of enzymes (glucose-6-phosphatase, hexokinase, phosphofructokinase, aldehyde dehydrogenase), hormones (leptin, ghrelin, insulin), insulin signaling molecules (Akt-PI3k, AMPK, JNK) hallmarks of inflammation (TNF-α), angiogenesis (VEGF), hypoxia (HIF-1), lipogenesis (mTOR) and regulatory nuclear transcription factors of de novo lipogenesis and hepatic insulin resistance gene (SREBP-1, FoxO1) that together govern the hepatic fructose metabolism, were also studied. The effect of fructose-rich environment on metabolic milieu of hepatocytes was confirmed using (human hepatocellular carcinoma) HepG2 cells. Using in vitro model, fructose uptake and glucose output from isolated murine hepatocytes were measured to establish the HepIR under fructose environment and delineate the effect of AM-HM. The leaves from the plant Aegle marmelos (L) Correa were extracted, fractionated and validated for rutin content using LC-MS/MS. The rutin content of extract was quantified and correlated with oral pharmacokinetic parameters in rat. The outcomes of the study suggest that the molecular and metabolic markers of fructose induced HepIR in developing and adult rats are distinct. Further, AM-HM exerts a multi-pronged attack by raising insulin secretion, augmenting insulin action, improving downstream signaling of insulin, reducing overall requirement of insulin and modulating hepatic expression of glucose transporter (Glut2). The butanol fraction of AM-HM holds promise for future development.
- 1 August 2017
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 438 (1-2) , 1-16
Aegle marmelos differentially affects hepatic markers of glycolysis, insulin signalling pathway, hypoxia, and inflammation in HepG2 cells grown in fructose versus glucose-rich environment
Fructose consumption is responsible for the onset of insulin resistance (IR), and metabolic syndrome. It possesses no functional utility in body and its detrimental effects on hepatic metabolic milieu are beyond those produced by glucose. The need of the hour is to identify fructose-induced IR as an unique pathological state to be managed differentially. The effect of aqueous leaf extract of Aegle marmelos (AM) on hepatic markers of insulin resistance using HepG2 cells cultured in either fructose or glucose-rich environment is investigated. Human hepatocellular carcinoma cells (HepG2) were grown under standard conditions in either—DMEM without glucose (NC), DMEM with high glucose 25 mM (Glu), DMEM-glucose+0.55 mM fructose (FC1), DMEM-glucose+1 mM fructose (FC2) or DMEM-glucose+1 mM fructose+0.1 µM insulin (FC3). The cells were treated with either AM, rutin, quercetin, metformin or pioglitazone and assessed for levels of hexokinase, phosphofructokinase (PFK), aldehyde dehydrogenase, phosphatidylinositol kinase (PI3K), signal transducer and activator of transcription-3 (STAT-3), mitochondrial target of rapamycin (mTOR), hypoxia-induced factor (HIF-1α), vascular endothelial growth factor (VEGF) and tumour necrosis factor (TNF-α). Summarily, when results from fructose- and glucose-rich environment were compared, then (1) IR was more pronounced in former; (2) AM performed better in former; (3) metformin and pioglitazone were equivocal in either; (4) rutin and quercetin showed deviant effects from AM; and lastly (5) effects of rutin were closer to AM than quercetin. We hypothesize that AM ameliorates fructose-induced IR through a mechanism which is distinct from standard drugs and not shared by individual phytoconstituents in toto.
- 1 August 2017
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 438 (1-2) , 1-16
Aegle marmelos differentially affects hepatic markers of glycolysis, insulin signalling pathway, hypoxia, and inflammation in HepG2 cells grown in fructose versus glucose-rich environment
Fructose consumption is responsible for the onset of insulin resistance (IR), and metabolic syndrome. It possesses no functional utility in body and its detrimental effects on hepatic metabolic milieu are beyond those produced by glucose. The need of the hour is to identify fructose-induced IR as an unique pathological state to be managed differentially. The effect of aqueous leaf extract of Aegle marmelos (AM) on hepatic markers of insulin resistance using HepG2 cells cultured in either fructose or glucose-rich environment is investigated. Human hepatocellular carcinoma cells (HepG2) were grown under standard conditions in either—DMEM without glucose (NC), DMEM with high glucose 25 mM (Glu), DMEM-glucose+0.55 mM fructose (FC1), DMEM-glucose+1 mM fructose (FC2) or DMEM-glucose+1 mM fructose+0.1 µM insulin (FC3). The cells were treated with either AM, rutin, quercetin, metformin or pioglitazone and assessed for levels of hexokinase, phosphofructokinase (PFK), aldehyde dehydrogenase, phosphatidylinositol kinase (PI3K), signal transducer and activator of transcription-3 (STAT-3), mitochondrial target of rapamycin (mTOR), hypoxia-induced factor (HIF-1α), vascular endothelial growth factor (VEGF) and tumour necrosis factor (TNF-α). Summarily, when results from fructose- and glucose-rich environment were compared, then (1) IR was more pronounced in former; (2) AM performed better in former; (3) metformin and pioglitazone were equivocal in either; (4) rutin and quercetin showed deviant effects from AM; and lastly (5) effects of rutin were closer to AM than quercetin. We hypothesize that AM ameliorates fructose-induced IR through a mechanism which is distinct from standard drugs and not shared by individual phytoconstituents in toto.